Shu Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Shu Zhang has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Andrew Yonemura
Cancer Biology Program, University of Hawaii Cancer Center, Honolulu, Hawaii
34 shared publications - Binyong Liang
Department of Bioengineering and Therapeutic Sciences and Liver Center, University of California, San Francisco, California
34 shared publications - Diego Francesco Calvisi
Institute of Pathology, University of Regensburg, Regensburg, Germany
34 shared publications - Eleonora Cossu
Institute of Pathology, University of Regensburg, Regensburg, Germany
34 shared publications - Guofei Cui
Department of Bioengineering and Therapeutic Sciences and Liver Center, University of California, San Francisco, California
34 shared publications - Haichuan Wang
Division of Liver Surgery, Department of General Surgery and Laboratory of Liver Surgery, West China Hospital, Sichuan University, Chengdu, China
34 shared publications
Latest Publications
- Open Access
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data S5 from Inhibition of GSK3 and TSC2 Mediates the Oncogenic Activity of AKT in Hepatocellular Carcinoma
List of down-regulated genes in Akt/NRas and sgGSK3α/β/NRas, but not in Tsc2-/-/NRas liver tumors
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data S5 from Inhibition of GSK3 and TSC2 Mediates the Oncogenic Activity of AKT in Hepatocellular Carcinoma
List of down-regulated genes in Akt/NRas and sgGSK3α/β/NRas, but not in Tsc2-/-/NRas liver tumors
- Open Access
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from Inhibition of GSK3 and TSC2 Mediates the Oncogenic Activity of AKT in Hepatocellular Carcinoma
Main characteristics of the plasmids used in the experiments
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from Inhibition of GSK3 and TSC2 Mediates the Oncogenic Activity of AKT in Hepatocellular Carcinoma
Main characteristics of the plasmids used in the experiments
- Open Access
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Inhibition of GSK3 and TSC2 Mediates the Oncogenic Activity of AKT in Hepatocellular Carcinoma
Foxo pathway in Akt/NRas driven HCC pathogenesis
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Inhibition of GSK3 and TSC2 Mediates the Oncogenic Activity of AKT in Hepatocellular Carcinoma
Foxo pathway in Akt/NRas driven HCC pathogenesis
- Open Access
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Inhibition of GSK3 and TSC2 Mediates the Oncogenic Activity of AKT in Hepatocellular Carcinoma
Histology analysis in liver tissues from Akt/NRas mice with overexpression of GSK3αS21A or GSK3βS9A
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Inhibition of GSK3 and TSC2 Mediates the Oncogenic Activity of AKT in Hepatocellular Carcinoma
Histology analysis in liver tissues from Akt/NRas mice with overexpression of GSK3αS21A or GSK3βS9A
- Open Access
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S18 from Inhibition of GSK3 and TSC2 Mediates the Oncogenic Activity of AKT in Hepatocellular Carcinoma
Correlation analysis of the expression between p-GSK3Ser9 and p-mTORCSer2448 and p-70S6KThr389 in human HCC samples from TCPA database
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S18 from Inhibition of GSK3 and TSC2 Mediates the Oncogenic Activity of AKT in Hepatocellular Carcinoma
Correlation analysis of the expression between p-GSK3Ser9 and p-mTORCSer2448 and p-70S6KThr389 in human HCC samples from TCPA database
- Open Access
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Inhibition of GSK3 and TSC2 Mediates the Oncogenic Activity of AKT in Hepatocellular Carcinoma
Plasmid dosages used for HCC murine models
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Inhibition of GSK3 and TSC2 Mediates the Oncogenic Activity of AKT in Hepatocellular Carcinoma
Plasmid dosages used for HCC murine models
- Open Access
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data S3 from Inhibition of GSK3 and TSC2 Mediates the Oncogenic Activity of AKT in Hepatocellular Carcinoma
List of down-regulated genes in Akt/NRas and Tsc2-/-/NRas, but not in sgGSK3α/β/NRas liver tumors
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data S3 from Inhibition of GSK3 and TSC2 Mediates the Oncogenic Activity of AKT in Hepatocellular Carcinoma
List of down-regulated genes in Akt/NRas and Tsc2-/-/NRas, but not in sgGSK3α/β/NRas liver tumors
- Open Access
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data S1 from Inhibition of GSK3 and TSC2 Mediates the Oncogenic Activity of AKT in Hepatocellular Carcinoma
List of up-regulated and down-regulated genes in Akt/NRas, Tsc2-/-/NRas, and sgGSK3α/β/NRas liver tumors
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data S1 from Inhibition of GSK3 and TSC2 Mediates the Oncogenic Activity of AKT in Hepatocellular Carcinoma
List of up-regulated and down-regulated genes in Akt/NRas, Tsc2-/-/NRas, and sgGSK3α/β/NRas liver tumors
- Open Access
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S8 from Inhibition of GSK3 and TSC2 Mediates the Oncogenic Activity of AKT in Hepatocellular Carcinoma
Unique pathways upregulated in Tsc2-/-/NRas and sgGSK3α/β/NRas liver tumors
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S8 from Inhibition of GSK3 and TSC2 Mediates the Oncogenic Activity of AKT in Hepatocellular Carcinoma
Unique pathways upregulated in Tsc2-/-/NRas and sgGSK3α/β/NRas liver tumors
- Open Access
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from Inhibition of GSK3 and TSC2 Mediates the Oncogenic Activity of AKT in Hepatocellular Carcinoma
Primary antibodies information for immunohistochemistry
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4 from Inhibition of GSK3 and TSC2 Mediates the Oncogenic Activity of AKT in Hepatocellular Carcinoma
Primary antibodies information for immunohistochemistry